Nothing Special   »   [go: up one dir, main page]

DE60103927D1 - Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems - Google Patents

Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems

Info

Publication number
DE60103927D1
DE60103927D1 DE60103927T DE60103927T DE60103927D1 DE 60103927 D1 DE60103927 D1 DE 60103927D1 DE 60103927 T DE60103927 T DE 60103927T DE 60103927 T DE60103927 T DE 60103927T DE 60103927 D1 DE60103927 D1 DE 60103927D1
Authority
DE
Germany
Prior art keywords
production
ventilation system
treating disorders
piperazine derivatives
central ventilation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60103927T
Other languages
English (en)
Other versions
DE60103927T2 (de
Inventor
Everett Childers
Gerard Kelly
Joy Rosenzweig-Lipson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Application granted granted Critical
Publication of DE60103927D1 publication Critical patent/DE60103927D1/de
Publication of DE60103927T2 publication Critical patent/DE60103927T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60103927T 2000-11-28 2001-11-27 Piperazinderivate, deren Herstellung und deren Verwendung in der Behandlung von Störungen des Zentralnervensystems Expired - Lifetime DE60103927T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25330100P 2000-11-28 2000-11-28
US253301P 2000-11-28
US29781401P 2001-06-13 2001-06-13
US297814P 2001-06-13
PCT/US2001/043160 WO2002044142A2 (en) 2000-11-28 2001-11-27 Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders

Publications (2)

Publication Number Publication Date
DE60103927D1 true DE60103927D1 (de) 2004-07-22
DE60103927T2 DE60103927T2 (de) 2005-06-23

Family

ID=26943115

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60103927T Expired - Lifetime DE60103927T2 (de) 2000-11-28 2001-11-27 Piperazinderivate, deren Herstellung und deren Verwendung in der Behandlung von Störungen des Zentralnervensystems

Country Status (25)

Country Link
US (3) US6469007B2 (de)
EP (1) EP1339406B1 (de)
JP (1) JP4198989B2 (de)
KR (1) KR100835552B1 (de)
CN (1) CN100352437C (de)
AR (1) AR035603A1 (de)
AT (1) ATE269078T1 (de)
AU (2) AU3765402A (de)
BR (1) BR0115609A (de)
CA (1) CA2428039C (de)
DE (1) DE60103927T2 (de)
DK (1) DK1339406T3 (de)
EA (1) EA005925B1 (de)
ES (1) ES2222401T3 (de)
HK (1) HK1057864A1 (de)
HU (1) HUP0400551A2 (de)
IL (1) IL156098A0 (de)
MX (1) MXPA03004677A (de)
NO (1) NO325501B1 (de)
NZ (1) NZ526150A (de)
PL (1) PL363219A1 (de)
PT (1) PT1339406E (de)
TR (1) TR200401546T4 (de)
TW (1) TWI224102B (de)
WO (1) WO2002044142A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432826B1 (en) * 1999-11-29 2002-08-13 Applied Materials, Inc. Planarized Cu cleaning for reduced defects
US20060287335A1 (en) * 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
US20060223824A1 (en) * 2000-11-28 2006-10-05 Wyeth Serotonergic agents
WO2003007956A1 (en) * 2001-07-20 2003-01-30 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
US7361773B2 (en) 2002-03-12 2008-04-22 Wyeth Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
JP2005527530A (ja) 2002-03-12 2005-09-15 ワイス キラル1,4−二置換ピペラジン
US7091349B2 (en) 2002-03-12 2006-08-15 Wyeth Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution
AU2003220094B2 (en) 2002-03-12 2009-04-23 Wyeth, A Corporation Of The State Of Delaware Process for synthesizing chiral N-aryl piperazines
GB0219961D0 (en) * 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
WO2004082686A2 (en) * 2003-03-13 2004-09-30 Dynogen Pharmaceuticals, Inc. Use of compounds with combined 5-ht1a and ssri activities to treat sexual dysfunction
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
US20070099931A1 (en) * 2004-03-19 2007-05-03 Wyeth Pharmaceutical dosage forms and compositions
US20050209245A1 (en) * 2004-03-19 2005-09-22 Wyeth Process for preparing N-aryl-piperazine derivatives
KR100646337B1 (ko) * 2004-06-30 2006-11-23 주식회사 롯데기공 보일러의 누수 감지방법
AU2005295640B2 (en) 2004-10-15 2011-07-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multi-domain amphipathic helical peptides and methods of their use
TW200700413A (en) * 2005-03-01 2007-01-01 Wyeth Corp Crystalline and amorphous 4-cyano-n-{(2r)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-n-pyridin-2-yl-benzamide hydrochloride
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
CA2612109A1 (en) * 2005-06-17 2006-12-28 Wyeth Tricyclic compounds useful as serotonin inhibitors and 5-ht1a agonists and antagonists
WO2007089616A2 (en) * 2006-01-26 2007-08-09 The University Of Rochester Inhibiting amyloid-beta peptide/rage interaction at the blood-brain barrier
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
AR063984A1 (es) * 2006-11-28 2009-03-04 Wyeth Corp Metabolitos de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina, metodos de preparacion, su uso en la fabricacion de medicamentos para el tratamiento de trastornos relacionados con 5-ht1a, composicion farmaceutica que los comprende, compuestos radioetiquetados derivado
CL2008000119A1 (es) 2007-01-16 2008-05-16 Wyeth Corp Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
US8936787B2 (en) * 2008-04-15 2015-01-20 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Peptides promoting lipid efflux

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645681B2 (en) 1991-05-02 1994-01-20 John Wyeth & Brother Limited Piperazine derivatives
GB9514901D0 (en) 1995-07-20 1995-09-20 American Home Prod Piperazine derivatives

Also Published As

Publication number Publication date
EA005925B1 (ru) 2005-08-25
TR200401546T4 (tr) 2004-09-21
EA200300619A1 (ru) 2003-10-30
US7026320B2 (en) 2006-04-11
CA2428039A1 (en) 2002-06-06
MXPA03004677A (es) 2003-09-05
DK1339406T3 (da) 2004-09-27
TWI224102B (en) 2004-11-21
PT1339406E (pt) 2004-10-29
NZ526150A (en) 2004-11-26
CA2428039C (en) 2011-08-09
KR100835552B1 (ko) 2008-06-09
HUP0400551A2 (en) 2006-02-28
IL156098A0 (en) 2003-12-23
JP4198989B2 (ja) 2008-12-17
JP2004520289A (ja) 2004-07-08
EP1339406B1 (de) 2004-06-16
NO325501B1 (no) 2008-05-26
AR035603A1 (es) 2004-06-16
AU3765402A (en) 2002-06-11
DE60103927T2 (de) 2005-06-23
BR0115609A (pt) 2003-11-11
WO2002044142A3 (en) 2002-08-08
US6469007B2 (en) 2002-10-22
ES2222401T3 (es) 2005-02-01
US20030216408A1 (en) 2003-11-20
US20030022901A1 (en) 2003-01-30
AU2002237654B2 (en) 2005-07-28
US20020107254A1 (en) 2002-08-08
NO20032390L (no) 2003-07-22
KR20030051879A (ko) 2003-06-25
EP1339406A2 (de) 2003-09-03
US6586436B2 (en) 2003-07-01
PL363219A1 (en) 2004-11-15
WO2002044142A2 (en) 2002-06-06
NO20032390D0 (no) 2003-05-27
ATE269078T1 (de) 2004-07-15
HK1057864A1 (en) 2004-04-23
CN1477961A (zh) 2004-02-25
CN100352437C (zh) 2007-12-05

Similar Documents

Publication Publication Date Title
DE60103927D1 (de) Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems
DE602004015269D1 (de) Piperazin derivate und ihre verwendung für die behandlung von neurologischen und psychiatrischen krankheiten.
ATE294171T1 (de) Phenylsulfonyl-1,3-dihydro-2h-indol-2-on derivate,deren herstellung und deren therapeutische verwendung
DE60233265D1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
ATE447561T1 (de) Substituierte aryl 1,4-pyrazin derivate
DE60319865D1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
DE60136736D1 (de) Pyrimidinonderivate und deren verwendung bei der behandlung von atherosklerose
ATE420097T1 (de) Substituierte sapogenine und ihre verwendung
ATE420866T1 (de) 4-(phenylpiperazinylmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
NO20014303D0 (no) JAK-3-inhibitorer for behandling av allergiske lidelser
ATE296634T1 (de) (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
DE60023012D1 (de) 3(5)-amino-pyrazolderivate, deren herstellungsverfahren und verwendung als krebshemmende mittel
DE69901177D1 (de) Platinkomplex, dessen herstellung und dessen therapeutische verwendung
ATE332294T1 (de) Dihydro-1,3,5-triazin-diamin-derivate und ihre therapeutische verwendung
ATE261972T1 (de) 2,5-diazabicyclo(2.2.1)heptanderivate, deren herstellung und deren verwendung in heilkunde
DE10084441T1 (de) Koalinton-Pigmente, ihre Herstellung und Verwendung
EE200200442A (et) Piperasiini ja piperidiini derivaadid neuronaalsete kahjustuste raviks
ATE384699T1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
DE69833297D1 (de) Substituierte Pyridylmethylpiperazin- und piperidinderivate, deren Herstellung und deren Verwendung in der Behandlung von Erkrankungen des Zentralnervensystems (ZNS)
DE69523654D1 (de) Verwendung von Ascorbyl-gamma-Linolenat und von Ascorbyl-dihomo-gamma-linolenat zur Behandlung von Asthma, Krebs, kardiovaskulären und inflammatorischen Erkrankungen
NO20031903L (no) Nye amidoalkylpiperidin- og amidoalkylpiperazinderivater for anvendelse vedbehandling av nervesystemlidelser
DE60009155D1 (de) Substituierte phenyl-piperazin-derivate, deren herstellung und verwendung
DE59510604D1 (de) UV-Absorber, ihre Herstellung und Verwendung
ATE251170T1 (de) Titanverbindungen, deren herstellung und verwendung
ATE303379T1 (de) 4-(phenyl-piperidin-4-ylidenmethyl)-benzamid- derivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition